vaccinia
viru
vacv
use
extens
human
immun
vaccin
almost
two
centuri
vacv
employ
provid
crossprotect
variola
viru
caus
agent
smallpox
diseas
erad
late
sinc
time
continu
research
vacv
produc
number
modifi
vaccin
improv
safeti
profil
attenu
achiev
sever
strategi
includ
sequenti
passag
altern
host
delet
specif
gene
genet
engin
viral
gene
encod
immunomodulatori
protein
highli
attenu
thirdand
fourthgener
vacv
vaccin
consid
stockpil
possibl
reintroduct
smallpox
bioterror
research
also
taken
advantag
abil
vacv
genom
accommod
addit
genet
materi
produc
novel
vaccin
wide
varieti
infecti
agent
includ
recombin
vacv
encod
rabi
viru
glycoprotein
administ
oral
wild
anim
review
provid
indepth
examin
success
gener
vacv
vaccin
focus
understand
poxvir
replic
viral
gene
function
permit
deliber
modif
vacv
immunogen
virul
vaccin
smallpox
first
introduc
edward
jenner
year
ago
singl
effect
public
health
intervent
human
histori
origin
farm
gloucestershir
england
vaccin
spread
around
world
lead
eventu
global
campaign
erad
smallpox
late
although
elimin
diseas
follow
termin
nation
vaccin
program
interest
vacv
smallpox
vaccin
end
past
three
decad
number
novel
attenu
variant
vacv
improv
safeti
profil
produc
varieti
laboratori
method
time
abil
vacv
genom
accommod
addit
genet
materi
enabl
molecular
virologist
produc
larg
number
candid
vaccin
target
wide
rang
microbi
pathogen
articl
review
vacv
develop
past
four
decad
candid
vaccin
varieti
use
discuss
genet
engin
could
lead
futur
new
vacv
vaccin
safe
highli
immunogen
first
discuss
replic
immunogen
wildtyp
wt
vacv
employ
smallpox
vaccin
campaign
firstgener
vacv
newer
form
wt
secondgener
vacv
stockpil
defens
possibl
reintroduct
smallpox
terrorist
review
form
thirdgener
vacv
attenu
sequenti
passag
altern
host
fourthgener
virus
produc
engin
vacv
genom
examin
potenti
need
rapidli
immunogen
form
vacv
could
use
postexposur
vaccin
event
reintroduct
smallpox
bioterror
final
section
review
vacv
use
vehicl
develop
novel
vaccin
heterolog
agent
discuss
futur
effort
focu
safeti
immunogen
famili
poxvirida
divid
genera
greatest
interest
human
genu
orthopoxviru
includ
variola
viru
agent
smallpox
cowpox
viru
origin
vaccin
use
jenner
vacv
appar
replac
cowpox
viru
use
vaccin
time
th
centuri
highli
conserv
natur
orthopoxviru
structur
protein
immun
vacv
provid
crossprotect
variola
orthopoxvirus
monkeypox
poxvirus
larg
genom
nucleotid
allow
insert
high
level
express
larg
foreign
gene
make
ideal
recombin
vaccin
vector
sever
featur
poxviru
replic
cycl
also
influenc
agent
employ
vaccin
soon
virion
core
enter
cell
earli
gene
transcript
result
product
wide
varieti
immunomodulatori
protein
block
innat
antivir
defens
includ
type
interferon
ifn
respons
discuss
delet
modif
viral
gene
prove
effect
method
modifi
vacv
virul
later
replic
cycl
infecti
viru
produc
first
form
intracellular
matur
virion
mv
form
basi
vacv
vaccin
matur
requir
produc
extracellular
envelop
virion
ev
requir
extracellular
spread
vacv
delet
gene
encod
ev
protein
also
result
attenu
vacv
vaccin
see
histor
first
effort
immun
smallpox
practic
earli
ce
involv
process
known
variol
radetski
involv
deliber
inocul
either
insuffl
scarif
fenner
individu
use
variola
viru
obtain
smallpox
pustul
patient
activ
diseas
typic
result
sever
local
reaction
gener
rash
constitut
symptom
case
fatal
rate
compar
follow
natur
variola
infect
despit
high
incid
complic
variol
commonli
practic
begin
th
centuri
orthopox
virus
antigen
relat
immun
nearli
orthopoxviru
protect
challeng
orthopoxvirus
figur
late
edward
jenner
discov
cowpox
viru
could
use
success
protect
human
smallpox
sinc
vaccin
cowpox
much
safer
variol
quickli
becam
primari
method
confer
protect
time
vacv
replac
cowpox
viru
agent
use
vaccin
note
vacv
genet
distinct
either
cowpox
viru
variola
viru
origin
remain
unknown
although
close
relat
horsepox
viru
tulman
et
al
jennerian
vaccin
virus
repres
st
gener
orthopox
viru
vaccin
vector
tabl
human
known
natur
reservoir
variola
viru
due
effect
vacv
vaccin
intensifi
global
smallpox
erad
program
begun
parrino
graham
rotz
et
al
basic
strategi
program
involv
mass
vaccin
campaign
countri
develop
surveil
system
detect
contain
outbreak
thank
measur
last
natur
occur
case
smallpox
occur
somalia
may
world
health
assembl
certifi
world
free
natur
occur
smallpox
rotz
et
al
wehrl
activ
licens
produc
vacv
vaccin
unit
state
discontinu
product
gener
use
distribut
civilian
popul
discontinu
rotz
et
al
smallpox
erad
program
major
vaccin
manufactur
skin
live
anim
includ
calv
sheep
buffalo
rabbit
mani
vacv
strain
use
erad
program
new
york
citi
board
health
nycbh
strain
use
america
west
africa
follow
erad
program
continu
august
wyeth
laboratori
inc
vaccin
commerci
approv
smallpox
vaccin
avail
limit
use
unit
state
rosenth
et
al
vaccin
manufactur
lymph
fluid
calv
skin
infect
nycbh
strain
strain
use
russia
deriv
nycbh
strain
wide
use
erad
smallpox
india
lister
listerelstre
strain
develop
lister
institut
unit
kingdom
lister
strain
becam
wide
use
vaccin
throughout
world
rosenth
et
al
addit
vaccin
strain
includ
pari
strain
franc
copenhagen
cop
strain
denmark
bern
strain
switzerland
ankara
strain
turkey
templ
heaven
vaccinia
tian
tan
vtt
strain
china
dairen
strain
japan
studi
suggest
advers
complic
vari
consider
among
differ
vaccin
strain
kretzschmar
et
al
overal
vaccin
nycbh
strain
caus
lowest
rate
advers
effect
wherea
vaccin
lister
strain
led
intermedi
rate
advers
effect
copenhagen
strain
led
intermediatehigh
rate
advers
event
bern
strain
led
highest
rate
advers
reaction
kretzschmar
et
al
typic
follow
vaccin
vesicular
pustular
skin
lesion
site
inocul
indic
success
vaccin
take
current
concern
variola
viru
reintroduc
human
popul
bioterror
event
emerg
monkeypox
signific
human
pathogen
use
efficaci
safeti
vacv
vaccin
reevalu
kretzschmar
et
al
neff
et
al
parrino
graham
forti
vaccine
report
mild
pain
site
inocul
report
pain
sever
fever
common
vaccin
report
kretzschmar
et
al
rotz
et
al
addit
mani
vaccine
report
varieti
mild
system
complic
includ
headach
myalgia
chill
nausea
fatigu
tabl
moder
sever
complic
vacv
vaccin
includ
eczema
vaccinatum
vaccine
histori
eczema
atop
dermat
gener
vaccinia
progress
vaccinia
immunocompromis
vaccine
myopericard
postvaccini
enceph
mostli
children
tabl
moder
sever
complic
occur
approxim
individu
per
million
primari
vaccin
rotz
et
al
recent
identifi
high
incid
myopericard
increas
surveil
cardiac
event
clinic
trial
futur
smallpox
vaccin
imperit
sniadack
et
al
abil
live
vacv
vaccin
replic
gener
protect
immun
respons
follow
challeng
well
document
replic
capac
vaccin
tissu
cultur
cell
shown
broad
host
rang
well
abil
replic
multipl
cell
type
laboratori
set
virus
routin
grown
kidneyderiv
cell
line
made
nonhuman
primat
vero
cell
abdalrhman
et
al
meseda
et
al
zhu
et
al
rabbit
kidokoro
et
al
hamster
vijaysri
et
al
sourc
kidneyderiv
fibroblast
cell
line
seem
especi
permiss
replic
therefor
wide
use
prepar
viral
stock
may
due
presenc
inhibitor
interferoninduc
pkr
protein
partial
character
cell
lab
langland
jacob
unpublish
observ
epitheli
fibroblast
cell
line
human
cervix
lung
tissu
hela
sharon
et
al
verardi
et
al
wyatt
et
al
murin
fibroblast
cell
line
verardi
et
al
zhu
et
al
also
use
grow
viral
stock
well
test
viral
replic
capac
host
rang
abil
particular
vacv
strain
grow
certain
cell
line
alway
correl
linearli
local
system
virul
vivo
abdalrhman
et
al
fang
et
al
verardi
et
al
therefor
replic
capac
vacv
character
measur
viral
load
tissu
vaccin
infect
highli
neuropathogen
western
reserv
wr
strain
origin
passag
nycbh
strain
mice
replic
high
titer
nose
lung
brain
ovari
skin
speci
brandt
et
al
jentarra
et
al
vijaysri
et
al
wyeth
lister
strain
also
replic
well
lung
mice
replic
least
three
order
magnitud
lower
brain
wr
follow
intranas
infect
abdalrhman
et
al
hayasaka
et
al
nycbh
grow
nearli
well
wr
skin
mice
wyeth
strain
isol
grow
lower
titer
wr
lee
et
al
concurr
replic
skin
format
pock
signifi
posit
vaccin
take
dose
plaqueform
unit
pfu
wr
requir
pock
format
mice
vacv
lister
requir
pfu
sharon
et
al
discrep
two
strain
could
due
fact
wr
neuroadapt
strain
may
replic
well
skin
administ
lower
dose
despit
higher
take
effici
lister
strain
log
higher
dose
requir
fulli
protect
mice
upon
wild
type
lethal
challeng
sharon
et
al
contrast
dose
pfu
nycbh
cop
strain
give
mild
pock
format
suffici
protect
mice
lethal
wild
type
challeng
tabl
summari
take
may
indic
certain
level
local
system
viral
replic
may
necessarili
enough
complet
protect
anim
lethal
challeng
tradit
dose
pfu
replic
wt
vacv
strain
given
induc
protect
human
although
note
dilut
appear
provid
protect
immun
couch
et
al
miller
et
al
histor
protect
smallpox
human
found
due
presenc
neutral
antibodi
sera
infect
individu
downi
mccarthi
mack
et
al
experi
use
mice
vaccin
challeng
wt
vacv
neutral
antibodi
measur
vaccin
vacv
lister
highest
dose
pfu
abdalrhman
et
al
higher
dose
neutral
antibodi
level
steadili
increas
year
follow
vaccin
ferrierrembert
et
al
howev
induct
protect
alway
correl
level
neutral
antibodi
induc
upon
vaccin
scarif
pfu
vacv
wr
induc
high
level
neutral
antibodi
scarif
dose
either
weaker
vacv
nycbh
vacv
cop
strain
induc
high
level
neutral
antibodi
nevertheless
provid
protect
lethal
challeng
unpublish
observ
immun
wt
vacv
induc
activ
lymphocyt
serv
addit
correl
protect
human
immun
pfu
induc
effector
cell
popul
cell
produc
upon
ex
vivo
stimul
month
postvaccin
cell
display
memori
cell
marker
month
postvaccin
cell
reactiv
miller
et
al
mice
scarif
vacv
lister
induc
cell
measur
month
postvaccin
ferrierrembert
et
al
specif
involv
cell
test
antibodi
deplet
studi
naiv
mice
follow
challeng
cell
requir
prevent
weight
loss
anim
presum
provid
nonspecif
cellmedi
respons
advent
humor
respons
belyakov
et
al
support
import
earli
nonspecif
cellmedi
respons
seen
immun
bcelldefici
mice
upon
challeng
anim
display
initi
weight
loss
recov
complet
belyakov
et
al
use
live
anim
product
vaccin
materi
chang
due
current
unaccept
process
qualiti
control
issu
regard
microbi
contamin
led
product
second
gener
smallpox
vaccin
use
tissu
cultur
system
embryon
chicken
egg
vacv
vaccin
prepar
embryon
chicken
egg
use
larg
scale
erad
campaign
south
america
standard
commerci
vaccin
israel
howev
experi
vaccin
materi
produc
cell
cultur
limit
vaccin
prepar
chick
embryo
fibroblast
japan
erad
diseas
effect
well
document
fenner
second
gener
smallpox
vaccin
licens
use
unit
state
august
vaccin
deriv
plaqu
purif
isol
subsequ
manufactur
vero
monkey
cell
line
popul
percentag
take
complic
use
similar
vaccine
also
found
accept
booster
previous
vaccin
smallpox
nevertheless
signific
minor
popul
contraind
prevent
preexposur
use
first
second
gener
smallpox
vaccin
greenberg
kennedi
therefor
substanti
work
direct
toward
develop
safer
yet
immunogen
vaccin
third
gener
vaccin
involv
genet
alter
vacv
genom
order
creat
nonrepl
highli
attenu
vacv
strain
still
retain
immun
properti
smallpox
one
commonli
use
techniqu
attenu
vacv
involv
multipl
passag
wt
virus
tissu
cultur
cell
altern
host
shown
alter
properti
viral
host
rang
virul
genom
composit
passag
virus
altern
host
use
year
obtain
attenu
viral
strain
monath
arguabl
effect
human
viral
vaccin
yellow
fever
viru
vaccin
obtain
nearli
passag
yellow
fever
viru
primari
mous
chicken
cell
cultur
case
vacv
three
current
vaccin
candid
obtain
passag
altern
host
lister
clone
modifi
vaccinia
ankara
mva
dairen
strain
di
develop
japan
passag
lister
strain
primari
rabbit
kidney
epitheli
cell
prk
low
temperatur
c
kenner
et
al
lister
viru
initi
passag
time
prk
cell
individu
clone
evalu
growth
monkey
kidney
vero
cell
order
gaug
abil
replic
primat
tissu
grew
lowest
titer
vero
cell
passag
time
ident
condit
form
mediums
pock
chick
chorioallanto
membran
cam
isol
stock
passag
time
prk
cell
isol
latter
stock
clone
replic
poorli
vero
cell
form
small
plaqu
cam
prk
cell
vivo
strain
take
rate
similar
lister
strain
temperaturerestrict
limit
host
rang
greatli
reduc
advers
effect
includ
neurovirul
kenner
et
al
vitro
phenotyp
clone
attribut
frameshift
singl
nucleotid
delet
gene
contrast
lister
virus
morikawa
et
al
takahashinishimaki
et
al
gene
encod
ev
protein
homolog
complement
regulatori
protein
takahashinishimaki
et
al
essenti
effici
ev
format
ev
necessari
effect
viru
dissemin
cell
cultur
within
infect
host
herrera
et
al
presum
lack
ev
format
cell
infect
lead
small
plaqu
phenotyp
rk
cell
failur
form
plaqu
vero
cell
sinc
phenotyp
caus
singl
base
pair
delet
strain
easili
revert
wild
type
version
small
plaqu
phenotyp
particular
unstabl
passag
kidokoro
et
al
stabil
version
contain
delet
entir
gene
develop
overcom
problem
kidokoro
et
al
mutat
respons
temperatur
restrict
vivo
attenu
phenotyp
may
likewis
unstabl
relev
loci
yet
map
larg
delet
genom
compar
nonattenu
strain
major
open
read
frame
orf
vacv
cop
open
morikawa
et
al
vacv
contain
mutat
found
may
uniqu
util
peopl
preexist
immun
vacv
sinc
primari
target
neutral
antibodi
respons
ev
bell
et
al
viner
et
al
theoriz
delet
gene
would
mean
overcom
preexist
immun
vacv
among
receiv
smallpox
vaccin
also
report
delet
conjunct
use
thymidin
kinas
tk
locu
express
heterolog
protein
result
vector
reduc
virul
howev
lack
induct
immun
may
make
less
effici
vaccin
protect
orthopoxvirus
mva
deriv
late
passag
chorioallantoi
vacv
ankara
cva
strain
vacv
time
chick
embryo
fibroblast
cef
cell
result
host
rang
restrict
viru
replicationdefect
mammalian
cell
mccurdi
et
al
highli
attenu
strain
unabl
replic
human
cell
clinic
trial
present
advers
reaction
sutter
moss
mva
safe
use
vaccin
peopl
germani
mayr
yet
effect
smallpox
remain
untest
intermedi
viru
attenu
mice
obtain
passag
cef
cell
four
larg
delet
two
left
right
speciesspecif
termin
region
vacv
genom
compar
cva
region
genom
contain
nonessenti
gene
often
involv
evas
host
innat
immun
respons
gene
necessari
maintain
broad
host
rang
vacv
mva
sever
addit
larg
delet
termin
arm
contain
numer
point
mutat
rel
fulli
replicationcompet
vacv
strain
antoin
et
al
meyer
et
al
mva
appear
lost
nearli
kb
genom
inform
consequ
mva
replic
effici
cef
bhk
cell
replic
restrict
human
cell
test
wyatt
et
al
viru
highli
attenu
mice
cell
mva
make
earli
intermedi
late
protein
immatur
virion
form
sutter
moss
uniqu
host
rang
restrict
vacv
identifi
lead
block
viral
protein
synthesi
meng
et
al
oppos
block
viral
matur
cva
mva
contain
delet
host
rang
gene
gene
essenti
replic
perku
et
al
cell
restor
miss
sequenc
gene
restor
replic
virus
cell
partial
restor
replic
human
vero
cell
restor
replic
mva
human
hela
cell
restor
pathogen
mice
meyer
et
al
wyatt
et
al
thu
mva
contain
addit
host
rangerestrict
mutat
addit
delet
addit
mutat
appear
affect
nonoverlap
read
frame
left
termin
region
genom
restor
region
entireti
lead
near
normal
host
rang
wyatt
et
al
mva
extens
studi
gold
standard
vacvbas
vaccin
consid
effect
provid
complet
antigen
dose
complet
alreadi
initi
replic
cycl
import
characterist
gener
antibodi
late
viral
envelop
protein
requir
neutral
vacv
yet
safe
go
cycl
primari
human
cell
blanchard
et
al
ludwig
et
al
mva
show
similar
antibodi
profil
produc
antibodi
membran
core
protein
davi
et
al
mva
shown
induc
protect
immun
respons
monkeypox
viru
nonhuman
primat
addit
delet
host
rang
gene
may
limit
mva
replic
human
cell
mva
lack
number
immunomodulatori
gene
encod
solubl
receptor
type
type
ii
ifn
tumor
necrosi
factor
tnf
cc
chemokin
blanchard
et
al
lack
immunomodul
affect
viral
replic
cycl
block
host
protein
synthesi
effect
induc
apoptosi
rapidli
may
augment
antigen
present
immunogen
mva
chahroudi
et
al
larsson
et
al
howev
comparison
studi
vacvbas
smallpox
vaccin
suggest
higher
dose
multipl
dose
mva
requir
achiev
immun
protect
seen
singl
dose
wt
replic
vacv
mous
model
mva
use
log
higher
dose
primeboost
regimen
requir
get
vacvspecif
cell
igg
level
compar
singl
administr
commerci
vaccin
meseda
et
al
wyatt
et
al
similarli
anoth
studi
evalu
two
dose
mva
given
prior
attempt
reduc
advers
effect
regimen
inde
result
lessen
local
reaction
higher
neutral
antibodi
titer
similar
number
produc
cell
measur
compar
alon
frey
et
al
kennedi
greenberg
di
strain
vacv
obtain
serial
passag
parent
dairen
die
vaccin
strain
day
old
egg
tagaya
et
al
di
strain
first
notic
form
tini
plaqu
cam
contrast
parent
strain
isol
sever
round
pock
format
cam
di
contain
kb
delet
left
termin
region
vacv
genom
appar
occur
homolog
recombin
two
base
pair
sequenc
nearli
ident
ishii
et
al
delet
encompass
wellcharacter
host
rang
gene
well
ifn
resist
gene
consequ
di
highli
restrict
host
rang
simpli
restor
replac
suggest
exist
addit
yet
unknown
hostrang
gene
region
ishii
et
al
note
delet
hostrang
determin
region
vacv
similar
although
extens
region
delet
left
arm
genet
engin
third
gener
smallpox
vaccin
nyvac
di
mva
obtain
passag
altern
host
nonetheless
similar
among
three
virus
numer
differ
well
di
mva
obtain
passag
chicken
cell
larg
delet
host
rang
determin
region
make
virus
replic
defect
mammalian
cell
despit
similar
host
rang
mva
contain
function
host
rang
gene
gene
delet
di
mva
passag
extens
di
may
respons
addit
larg
delet
numer
small
insert
delet
present
mva
left
right
termin
arm
viru
addit
mutat
innat
immun
evas
gene
mva
may
respons
uniqu
abil
viru
among
nongenet
engin
orthopoxvirus
induc
proinflammatori
signal
transduct
proinflammatori
gene
express
lead
increas
migrat
immun
cell
site
immun
guerra
et
al
lehmann
et
al
abil
mva
induc
proinflammatori
cytokin
may
profound
influenc
abil
induc
adapt
immun
induct
proinflammatori
signal
proinflammatori
gene
express
di
report
obtain
passag
rabbit
kidney
cell
rather
larg
delet
one
singl
base
pair
delet
like
small
mutat
alter
gene
function
give
temperatur
restrict
low
pathogen
viru
intact
host
rang
determin
region
appear
replic
compet
mammalian
cell
thu
properti
virus
vaccin
may
differ
replic
compet
viru
may
properti
closer
wtvacv
di
mva
howev
failur
make
ev
may
least
potenti
affect
efficaci
replac
smallpox
vaccin
advanc
biotechnolog
allow
insert
delet
interrupt
gene
specif
genom
site
target
attenu
virus
becam
practic
goal
vacv
involv
delet
immunemodul
hostrang
accessori
nucleotid
metabol
gene
well
delet
essenti
gene
complement
cell
line
express
target
vacv
gene
goal
delet
gene
vacv
attenu
viru
maintain
increas
immunogen
attenu
certainli
attain
delet
gene
vacv
limit
evid
immunogen
increas
delet
gene
vacv
delet
one
three
gene
increas
tcell
respons
cottingham
et
al
jentarra
et
al
staib
et
al
singl
gene
delet
minim
effect
alcami
smith
alcami
smith
best
immunogen
appear
maintain
delet
gene
vacv
although
often
higher
dose
compar
wt
parent
may
due
need
delet
gene
famili
rather
singl
gene
limit
histor
analys
immun
respons
summari
modifc
genet
engin
shown
tabl
one
best
character
genet
attenu
mutant
vacv
nyvac
delet
open
read
frame
orf
tartaglia
et
al
delet
gene
includ
cassett
orf
span
host
rang
region
tk
hemorrhag
region
atyp
inclus
region
hemagglutinin
gene
orf
encod
larg
subunit
ribonucleotid
reductas
nyvac
deriv
vavc
cop
highli
attenu
human
cell
line
still
retain
abil
induc
strong
immun
respons
tartaglia
et
al
nonpermiss
cell
nyvac
progress
earli
stage
viral
replic
stop
najera
et
al
consequ
one
log
higher
dose
mva
requir
seroconvers
probabl
due
lack
late
stage
protein
express
ferrierrembert
et
al
cell
initi
compar
nyvac
mva
vacv
lister
longer
term
studi
day
suggest
lister
ultim
result
higher
cell
neutral
antibodi
mva
lister
produc
neutral
antibodi
within
day
postvaccin
even
nyvac
primeboost
regimen
ferrierrembert
et
al
vacv
gene
encod
homolog
secret
receptor
loss
gene
impair
abil
viru
block
activ
host
cytokin
thu
attenu
viru
verardi
et
al
yet
delet
prevent
replic
viru
human
mous
cell
vitro
addit
signific
differ
humor
cellular
immun
respons
immunocompet
mice
infect
deletedvacv
parent
viru
despit
prior
studi
suggest
gene
affect
virul
vacv
mice
alcami
smith
alcami
smith
mutant
caus
much
less
morbid
nude
mice
wt
viru
even
higher
dose
dene
et
al
delet
either
serin
proteas
inhibitor
serpin
gene
shown
legrand
et
al
attenu
vacv
replic
pathogen
mutant
virus
replicationcompet
murin
cell
viru
abl
replic
human
cell
howev
later
studi
indic
delet
host
immun
respons
system
modul
gene
vacv
littl
effect
virul
pathogen
suggest
contrast
find
studi
legrand
et
al
may
result
model
use
jackson
et
al
recent
sever
mutat
vtt
strain
analyz
vtt
strain
use
protect
million
peopl
peopl
republ
china
smallpox
strain
vacv
pathogen
immunesuppress
individu
dai
et
al
delet
two
nonessenti
immun
modulatori
gene
encod
bind
protein
encod
tnf
receptor
homologu
vtt
dai
et
al
delet
result
reduct
intracrani
ic
lethal
dose
ld
delet
yield
reduct
ic
ld
mice
delet
attenu
viru
rabbit
follow
inocul
scarif
delet
gene
ectromelia
viru
also
shown
attenu
mutat
born
et
al
mous
model
inocul
mouseadapt
wr
vacv
strain
delet
caus
less
sever
symptom
compar
wt
viru
read
smith
mutat
host
rang
region
vtt
also
use
attenu
viru
zhu
et
al
zhu
et
al
delet
fragment
contain
gene
ic
inocul
mice
mutant
viru
attenu
comparison
wild
type
viru
viru
replicationincompet
sever
cell
line
includ
hela
human
rabbit
vero
african
green
monkey
delet
host
rang
gene
reduc
replic
cell
delet
gene
along
serin
proteas
inhibitor
ankyrinlik
protein
earli
gene
reduc
vitro
replic
vaccin
requir
primeboost
regimen
neutral
antibodi
titer
cellmedi
respons
approach
observ
wt
vacv
vaccin
zhu
et
al
sever
virus
contain
mutat
accessori
nucleotid
metabol
gene
gene
encod
membran
secret
protein
analyz
attenu
immunogen
follow
work
done
develop
vaccinia
vector
express
foreign
antigen
earli
panicali
et
al
smith
et
al
smith
et
al
buller
et
al
show
vacv
delet
tk
gene
could
replic
normal
titer
local
follow
inocul
scarif
decreas
abil
dissemin
replic
intern
organ
buller
et
al
viru
attenu
log
compar
wt
control
one
first
applic
genet
engin
vacv
vaccin
use
combat
rabi
wildlif
gene
rabi
viru
glycoprotein
insert
vacv
place
tk
kieni
et
al
even
though
tkdelet
viru
attenu
one
case
human
infect
report
rupprecht
et
al
rais
issu
potenti
human
exposur
anim
vaccin
concomit
harm
human
contrast
delet
tk
delet
ribonucleotid
reductas
rr
hemaglutinin
ha
lee
et
al
viral
growth
factor
vgf
buller
et
al
affect
pock
format
skin
vacvantibodi
titer
viru
delet
tk
rr
ha
high
dose
vaccin
similar
achiev
follow
vaccin
parent
virus
low
dose
vaccin
vacvspecif
antibodi
level
rr
ha
delet
mutant
much
lower
anim
vaccin
wtvacv
lee
et
al
mutat
anoth
host
rangevirul
gene
result
rang
attenu
vacv
vacv
gene
product
prevent
induct
antivir
state
ifninduc
pathway
langland
jacob
complet
delet
gene
result
vacv
replicationdefici
human
cell
chang
et
al
vijaysri
et
al
studi
newborn
mice
wr
strain
delet
attenu
five
log
heck
denzler
jacob
unpublish
observ
immunocompet
mice
viru
replic
poorli
nasal
mucosa
still
induc
protect
immun
respons
vijaysri
et
al
result
increas
induct
mani
proinflammatori
gene
compar
mutant
langland
et
al
target
mutat
delet
either
nterminu
cterminu
also
result
attenu
yet
immunogen
version
parent
strain
phenotyp
rang
diseas
persist
infect
andor
clinic
diseas
higher
dose
scid
mice
chang
pogo
jentarra
et
al
langland
jacob
langland
jacob
vijaysri
et
al
anoth
strategi
attenu
vacv
without
lose
efficaci
replac
gene
partial
complement
homologu
gene
ambystoma
tigrinum
viru
also
sensit
treatment
cell
type
interferon
phenotyp
uniqu
amongst
mutant
vacv
scarif
studi
caus
signific
weight
loss
local
symptom
vaccin
protect
balbc
mice
prevent
diseas
includ
weight
loss
wtvacv
challeng
anoth
genet
attenu
mutant
late
defect
vacv
delet
essenti
gene
encod
enzym
uracil
dna
glycosylas
udg
open
read
frame
holzer
falkner
vacv
unabl
produc
late
gene
product
render
nonrepl
cell
cultur
order
overcom
obstacl
must
grown
complement
cell
line
express
miss
earli
viral
gene
holzer
falkner
nonrepl
late
defect
mutant
make
attract
vaccin
vector
due
abil
elicit
potent
immun
respons
express
earli
gene
fact
vacv
mutant
express
prme
gene
tickborn
enceph
tbe
found
protect
immunesuppress
mice
lethal
challeng
ld
virul
tbe
viru
pfu
furthermor
viru
rapidli
clear
immunesuppress
mice
even
highest
vaccin
dose
pfu
howev
lack
express
structur
gene
product
may
make
viru
unsuit
vaccin
protect
orthopoxvirus
vacv
also
attenu
insert
gene
encod
host
immun
respons
modul
flexner
et
al
demonstr
express
vacv
wr
strain
render
viru
nonpathogen
athym
nude
mice
viru
express
also
found
nonpathogen
athym
nude
mice
giavedoni
et
al
kohonencorish
et
al
mice
recov
infect
anoth
exampl
express
vacv
result
severalthousandfold
reduct
lethal
athym
nude
mice
still
induc
longerliv
memori
cell
oh
et
al
well
enhanc
humor
cellular
respons
immunocompet
mice
compar
unmodifi
viru
perera
et
al
mice
vaccin
vacv
surviv
lethal
challeng
wt
version
month
vaccin
wherea
mice
receiv
homolog
vaccin
succumb
perera
et
al
express
immunestimul
gene
may
hand
enhanc
immunogen
highli
attenu
nonrepl
vacv
instanc
mva
shown
infect
antigenpres
cell
includ
dendrit
cell
b
cell
macrophag
chahroudi
et
al
turn
activ
cell
ultim
induc
antigenspecif
adapt
cellmedi
respons
therefor
express
mva
cytokin
known
enhanc
activ
antigenpres
cell
could
augment
overal
immun
respons
vaccin
exampl
cytokin
includ
granulocytemacrophag
colonystimul
factor
macrophag
inflammatori
protein
fmslike
tyrosin
kinas
ligand
strategi
result
sixto
sevenfold
enhanc
mvaspecif
antibodi
titer
mous
experi
chavan
et
al
ultim
combin
strategi
may
need
attenu
wtvacv
enhanc
specif
immun
pathway
exampl
recombin
vacv
delet
serpin
proteas
inhibitor
express
replic
high
titer
tissu
cultur
avirul
immunodefici
immunocompet
mice
yet
induc
potent
vacvspecif
immun
respons
follow
septemb
potenti
use
smallpox
viru
varv
bioterror
agent
brought
special
attent
constitut
ideal
terrorist
weapon
mass
destruct
leduc
et
al
moreov
also
remain
low
real
risk
varv
releas
whether
intent
accident
thorn
et
al
reason
make
requir
postexposur
prophylaxi
smallpox
one
ultim
goal
nationwid
also
worldwid
postexposur
vaccin
vacv
suggest
effect
mean
minim
casualti
smallpox
exposur
long
vaccin
administ
within
four
day
initi
exposur
mortim
anecdot
evid
efficaci
postexposur
vaccin
definit
studi
human
anim
model
postexposur
vaccin
thu
far
consist
describ
sever
anim
studi
done
worthi
mention
intramuscular
im
vaccin
mva
shown
protect
mice
sever
diseas
death
mice
underw
respiratori
challeng
vacv
wr
strain
either
im
vaccin
howev
immun
protocol
fail
complet
prevent
clinic
sign
even
given
within
three
hour
challeng
complet
ineffect
given
one
four
day
postexposur
followup
studi
done
order
compar
rel
efficaci
shortterm
postexposur
vaccin
nonrepl
mva
replicationcompet
vacv
listerelstre
strain
mice
immun
scarif
listerelstre
strain
day
prior
challeng
protect
respiratori
challeng
vacv
wr
confirm
efficaci
prophylact
vaccin
vaccin
day
two
day
challeng
fail
protect
mortal
lack
efficaci
listerelstre
strain
given
coupl
day
preor
postchalleng
could
part
attribut
rout
inocul
scarif
although
im
inocul
improv
perform
shortterm
prophylact
therapeut
vaccin
thu
postexposur
vaccin
strain
particular
anim
model
seem
limit
anoth
studi
compar
effect
antivir
treatment
cidofovir
relat
acycl
nucleosid
phosphon
analog
hpmpodapi
postexposur
vaccin
use
standard
dose
recommend
human
listerelstre
strain
vacv
lethal
monkeypox
exposur
studi
suggest
multidos
antivir
treatment
within
hour
postinfect
could
reduc
mortal
cutan
lesion
comparison
standard
postexposur
vaccin
stittelaar
et
al
recent
studi
shown
mva
given
via
subcutan
inject
time
lethal
dose
ectromelia
viru
ectv
abl
protect
mice
death
abl
protect
defici
mice
administ
two
day
postchalleng
samuelsson
et
al
anoth
studi
efficaci
mva
listerelstre
strain
postexposur
vaccin
evalu
mice
follow
challeng
use
ectv
model
therapeut
immun
listerelstre
mva
im
provid
full
protect
administ
day
one
day
postinfect
moreov
protect
affect
vaccin
dose
improv
surviv
rate
vaccin
day
two
three
postinfect
paran
et
al
one
reason
listerelstre
mva
vaccin
effect
postexposur
treatment
ectv
vacv
wr
may
reli
differ
mean
time
death
observ
upon
infect
mice
infect
either
ectv
day
vacv
wr
day
well
absenc
neurovirul
observ
ectvinfect
mice
extend
period
observ
onset
diseas
may
essenti
allow
time
b
cell
mount
solid
immun
respons
recombin
activ
gene
mice
fail
confer
immun
shortterm
vaccin
paran
et
al
anoth
approach
postexposur
treatment
involv
use
vacv
express
vector
foreign
gene
cytokin
play
import
role
vacv
infect
recombin
vacv
express
cytokin
construct
known
decreas
vacv
virul
increas
virul
pathogen
vacv
infect
muller
et
al
ramshaw
et
al
sharma
et
al
convers
express
shown
clear
vacv
infect
coexpress
indic
synergist
action
cytokin
group
cytokin
includ
ifn
inhibit
viru
replic
vacvinfect
cell
liu
et
al
stimul
antigenpres
cell
recent
studi
optim
postexposur
prophylaxi
anim
infect
wt
vacv
success
achiev
treatment
recombin
vacv
express
one
day
post
infect
mortal
holechek
et
al
conclus
variou
approach
postexposur
prophylaxi
shown
promis
effect
prevent
diseas
anim
model
although
ectv
model
postexposur
prophylaxi
seem
promis
model
use
neuropathogen
wr
strain
could
inde
use
find
postexposur
treatment
harsher
onset
diseas
futur
studi
determin
either
replic
compet
highli
attenu
nonrepl
vacv
strain
safe
effect
use
postexposur
prophylaxi
approach
human
erad
smallpox
combin
advent
genet
engin
recombin
poxviru
technolog
demonstr
feasibl
use
vacv
protect
specif
pathogen
rel
eas
gener
recombin
vacv
express
heterolog
gene
widespread
attent
given
idea
use
vector
vehicl
antigen
deliveri
system
differ
diseas
moss
paoletti
date
recombin
poxviru
vaccin
vector
gener
target
mani
human
veterinari
infecti
diseas
cancer
perku
et
al
nearli
twenti
year
vacv
cop
util
campaign
elimin
rabi
wildlif
pastoret
brochier
oral
base
vaccin
consist
recombin
vacv
mildli
attenu
loss
tk
gene
function
express
rabi
glycoprotein
use
immun
red
fox
raccoon
coyot
skunk
part
unit
state
europ
campaign
success
elimin
rabi
part
europ
significantli
reduc
incid
rabi
unit
state
consequ
vaccin
oral
rabi
vaccin
licens
use
anim
unit
state
europ
vaccin
licens
use
human
still
current
use
safeti
issu
paramount
concern
vacvbas
vaccin
develop
complic
associ
replic
wt
vacv
perku
et
al
effort
circumv
advers
effect
vacv
technolog
turn
develop
highli
attenu
strain
vacv
exploit
use
diverg
hostrestrict
poxvirus
attempt
gener
safe
vaccin
platform
addit
immun
protocol
heterolog
primeboost
regimen
coexpress
immunemodulatori
molecul
appli
enhanc
immun
respons
poxviru
vector
current
variou
paramet
mode
inocul
rout
vaccin
administr
immun
schedul
also
investig
optim
immun
protocol
achiev
efficaci
safeti
gomez
et
al
address
safeti
issu
surround
vaccin
develop
extens
studi
done
use
replicationdefici
poxvirus
vaccin
vector
exampl
replicationdefici
poxvirus
orthopoxvirus
mva
nyvac
avipoxvirus
fowlpox
canarypox
alvac
mva
nyvac
attenu
vacv
contain
multipl
gene
delet
prevent
product
replic
cycl
mammalian
cell
wherea
avipoxvirus
natur
host
rang
restrict
replic
nonavian
cell
preclin
studi
shown
vector
induc
level
protect
mani
heterolog
agent
use
vaccin
human
veterinari
medicin
bisht
et
al
bublot
et
al
chen
et
al
kreijtz
et
al
mink
et
al
poulet
et
al
ramo
et
al
mva
nyvac
studi
extens
comprehens
review
publish
compar
vector
detail
variou
applic
vaccin
vector
gomez
et
al
due
safeti
profil
immun
potenti
mva
nyvac
prime
candid
hiv
vaccin
develop
use
countless
preclin
clinic
trial
studi
gomez
et
al
increas
attent
turn
toward
use
avipoxviru
vector
safe
altern
orthopoxviru
vector
thongcharoen
et
al
primeboost
regimen
includ
differ
combin
nonrepl
strain
becom
commonplac
enhanc
immun
avoid
complic
preexist
immun
vacv
vector
webster
et
al
woodland
despit
studi
show
highli
attenu
vector
capabl
induc
protect
immun
varieti
pathogen
limit
replic
still
gener
concern
abil
induc
immun
respons
effect
replicationcompet
counterpart
abaitua
et
al
dai
et
al
karkhani
ross
studi
compar
two
vector
vaccin
studi
clearli
demonstr
effort
safeti
often
long
term
protect
efficaci
lost
instanc
quest
safer
rabi
vaccin
recent
studi
compar
efficaci
variou
rabi
vaccin
candid
differ
vacv
strain
recombin
mva
prove
inferior
mount
immun
respons
mice
given
oral
immun
compar
cop
wr
strain
furthermor
oral
administr
vector
fail
elicit
memori
respons
previous
vaccin
dog
raccoon
therefor
deem
suitabl
replac
current
oral
vaccin
vrg
weyer
et
al
addit
recent
smallpox
vaccin
studi
emphas
superior
replic
compet
vector
non
replic
vector
long
term
protect
immunogen
lethal
cowpox
challeng
ferrierrembert
et
al
replicationcompet
recombin
vacvbas
vaccin
receiv
increas
attent
potenti
vaccin
vector
mani
infecti
diseas
sinc
presum
abl
elicit
potent
humor
cell
mediat
immun
respons
confer
last
protect
differ
approach
taken
lower
virul
enhanc
immun
respons
effort
gener
safe
vaccin
platform
mani
turn
delet
gene
encod
virul
factor
whose
function
evad
host
immun
respons
exampl
includ
solubl
cytokinechemokin
viroceptor
day
et
al
dene
et
al
symon
et
al
viral
serin
proteas
inhibitor
serpin
inhibitor
cellular
antivir
enzym
langland
et
al
immunogen
vector
attenu
delet
gene
greatli
affect
two
independ
studi
delet
gene
dene
et
al
verardi
et
al
result
viru
abl
replic
level
wt
version
vitro
yet
significantli
less
pathogen
mice
latter
immunolog
respons
delet
mutant
parent
viru
analyz
substanti
differ
observ
anoth
studi
delet
bind
protein
viral
tnf
receptor
homologu
result
viru
attenu
yet
viru
express
hiv
gene
abl
elicit
strong
humor
cellmedi
respons
hiv
protein
dai
et
al
anoth
exampl
attenu
reduct
virul
factor
function
work
perform
group
previous
discuss
langland
jacob
langland
jacob
langland
et
al
vijaysri
et
al
vacv
delet
serpin
protein
express
highli
attenu
immunocompromis
mice
elicit
potent
immun
respons
protect
challeng
homolog
heterolog
agent
collect
live
vaccin
vector
repres
promis
potenti
safe
effect
vaccin
platform
mani
genet
modifi
poxvirus
replicationdefect
characterist
long
consid
critic
develop
safe
vaccin
era
immun
defici
result
chemotherapi
organ
transplant
hiv
infect
diseas
impact
immun
system
unfortun
recent
anim
limit
human
data
suggest
third
fourth
gener
replicationdefect
vacv
vaccin
fact
less
immunogen
prior
vaccin
gener
although
vaccin
may
util
prime
agent
individu
contraind
second
gener
vaccin
artenstein
howev
necess
replicationcompet
vaccin
vector
becom
increasingli
theoriz
potenti
solut
lack
efficaci
vaccin
test
human
trial
recent
one
scrutin
unsuccess
trial
merck
hiv
vaccin
use
replicationdefect
adenoviru
vector
deliveri
hiv
antigen
http
wwwhvtnorgsciencestepreviewhtml
replic
compet
exclud
attenu
evidenc
report
parker
et
al
parker
et
al
studi
recombin
herp
simplex
viru
hsv
attenu
delet
gene
elimin
neurovirul
viru
still
replicationcompet
viru
grown
higher
titer
replicationdefect
hsv
vector
express
heterolog
antigen
higher
level
therefor
third
gener
attenu
replicationcompet
vaccin
candid
develop
provid
strong
immunolog
respons
reduc
advers
sideeffect
vacv
encod
number
protein
involv
inhibit
host
antivir
immunolog
inflammatori
respons
mutagenesi
delet
gene
often
lead
viral
construct
replicationcompet
reduc
pathogenesi
exampl
viral
gene
requir
inhibit
host
ifn
respons
discuss
review
mutat
gene
vacv
result
sever
replicationcompet
virus
greatli
reduc
virul
anim
retain
abil
protect
orthopoxviru
challeng
vijaysri
et
al
similarli
attenu
replicationcompet
vaccin
construct
addit
gene
vacv
genom
known
effect
modul
host
respons
improv
immunogen
perera
et
al
final
vacv
gene
replac
allow
singl
round
replic
human
cell
capabl
dissemin
activ
immun
respons
signal
transduct
pathway
jancovich
langland
talasela
jacob
unpublish
observ
therefor
confid
continu
effort
genet
modifi
poxviru
vector
improv
understand
virus
also
allow
preserv
safeti
take
advantag
immunogen
benefit
replic
compet
advers
event
associ
primari
vaccinia
vaccin
tabl
illustr
nycbh
strain
smallpox
vaccin
advers
event
rate
two
studi
done
lane
et
al
lane
et
al
current
advers
event
rate
may
expect
higher
due
increas
individu
immun
suppress
cancer
cancer
therapi
organ
transplant
ill
hivaid
eczema
atop
dermat
common
refer
vaccin
sorered
vaccin
site
common
vivo
replic
protect
vacv
use
murin
studi
st
nd
th
gener
replic
smallpox
vaccin
wr
